Nottingham Prognostic Index After Chemotherapy in Breast Cancer
Author Information
Author(s): Chollet P, Amat S, Belembaogo E, Curé H, de Latour M, Dauplat J, Le Bouëdec G, Mouret-Reynier M-A, Ferrière J-P, Penault-Llorca F
Primary Institution: Centre Jean Perrin
Hypothesis
Does the Nottingham prognostic index retain its prognostic value after induction chemotherapy in operable breast cancer?
Conclusion
The Nottingham prognostic index remains a significant prognostic tool after neoadjuvant chemotherapy in operable breast cancer.
Supporting Evidence
- The Nottingham prognostic index was validated in this study for patients after chemotherapy.
- Patients with a lower NPI score had better overall survival rates.
- Residual tumor size and lymph-node involvement were significant prognostic factors.
Takeaway
This study looked at how well a scoring system called the Nottingham prognostic index works for breast cancer patients after they have had chemotherapy. It found that the score is still useful for predicting how patients will do.
Methodology
The study evaluated the prognostic value of residual tumor characteristics after neoadjuvant chemotherapy in 451 patients with operable breast cancer.
Potential Biases
Potential biases may arise from the retrospective nature of the analysis and the selection of patients.
Limitations
The study's findings may not be generalizable due to the specific patient population and treatment protocols used.
Participant Demographics
Median age was 49 years, with 54.8% premenopausal women and 79.6% having invasive ductal carcinoma.
Statistical Information
P-Value
0.0006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website